Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2019-08-29 Governance Information
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
独立董事工作制度
Governance Information Classification · 95% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System'. It details the governance structure, qualifications, duties, rights, and obligations of independent directors within the company. The content focuses on internal governance rules, director responsibilities, and compliance with relevant laws and regulations. There is no financial data, no mention of annual or quarterly results, no voting results, no legal proceedings, no capital changes, or other financial or operational updates. The document is a governance framework document outlining internal rules and practices related to board members, specifically independent directors. Therefore, it fits the category of Governance Information (CGR). The document length is sufficient and the content is substantive, not a brief announcement or certification, so it is not RPA or RNS. Hence, the classification is CGR with high confidence.
2019-08-29 Chinese
发行股份购买资产并募集配套资金暨关联交易之非公开发行募集配套资金发行结果暨股本变动的公告
Capital/Financing Update Classification · 100% confidence The document is a detailed announcement regarding a non-public issuance of shares to raise funds, including specifics on the number of shares issued, pricing, subscription details, lock-up periods, shareholder changes before and after the issuance, and approvals from regulatory bodies such as the China Securities Regulatory Commission. It also includes information on the registration of shares, legal and financial advisor opinions, and the impact on control of the company. The document is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is a capital/financing update detailing the issuance of new shares and related capital changes. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-07-26 Chinese
北京国枫律师事务所关于中源协和细胞基因工程股份有限公司发行股份购买资产并募集配套资金暨关联交易之非公开发行股票发行过程及认购对象合规性的专项法律意见书
Regulatory Filings
2019-07-26 Chinese
发行股份购买资产并募集配套资金暨关联交易之实施情况暨新增股份上市公告书
Capital/Financing Update Classification · 100% confidence The document is a detailed announcement regarding the issuance of shares to purchase assets and the raising of supporting funds, including specifics on share issuance, pricing, approval processes, and implementation status. It includes detailed information about the transaction, share lock-up arrangements, profit compensation agreements, and registration of new shares. The document is titled as an "Implementation Situation and New Shares Listing Announcement" and contains extensive financial and procedural details about a major asset restructuring transaction. This matches the characteristics of a Capital/Financing Update (CAP) filing, which covers company fundraising, financing activities, or capital structure changes. It is not a full annual or interim report, nor a simple announcement of a report publication. Therefore, the correct classification is CAP.
2019-07-26 Chinese
发行股份购买资产并募集配套资金暨关联交易之实施情况暨新增股份上市公告书摘要
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the issuance of shares to purchase assets and the accompanying fundraising through a non-public stock issuance. It includes extensive information about the transaction structure, pricing, approval processes, implementation status, share lock-up arrangements, profit compensation agreements, and registration of new shares. The document references regulatory approvals from the China Securities Regulatory Commission and the U.S. Foreign Investment Committee, detailed financial advisor and legal opinions, and audit reports related to capital verification. The content is focused on the implementation and completion of a major asset acquisition and related capital raising, including the listing of new shares. This type of document is characteristic of a Capital/Financing Update (CAP), as it provides comprehensive updates on fundraising activities, share issuance, and capital structure changes related to a significant transaction. It is not a full annual or interim report, nor a simple announcement or proxy statement. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-07-26 Chinese
东兴证券股份有限公司关于中源协和细胞基因工程股份有限公司发行股份购买资产并募集配套资金暨关联交易实施情况之独立财务顾问核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed independent financial advisor's verification opinion regarding a company's issuance of shares to purchase assets and raise supporting funds, including related party transactions. It includes comprehensive information about the transaction structure, approval processes, asset valuation, share issuance, capital increase, and compliance with regulatory requirements. The document is lengthy (over 11,000 characters) and contains substantive financial and procedural details about a capital raising and asset acquisition transaction. This fits the definition of a Capital/Financing Update (CAP), as it provides updates on company fundraising, financing activities, and capital structure changes. It is not an announcement of a report, nor a full annual or interim report, nor a proxy or voting result. Therefore, the correct classification is CAP with high confidence.
2019-07-26 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.